Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment for the three months ending September 30, 2025 and 2024 is as follows:

	Three Months Ended September 30, 2025
	Cell Therapy			BioBanking		Degenerative Disease			Other			Total
Net revenues	$	1,592			1,448		2,244			—			5,284
Cost of revenues (excluding amortization of acquired intangible assets)		—			220		3,684			—			3,904
Direct expenses		4,079			365		1,358			8,102			13,904
Segment contribution	$	(2,487	)	$	863	$	(2,798	)	$	(8,102	)	$	(12,524	)
Indirect expenses										376	(a)		376
Loss from operations													(12,900	)
(a) Components of other
Amortization										376
Total other									$	376

	Three Months Ended September 30, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Other			Total
Net revenues	$	—			1,292		8,004		—			9,296
Cost of revenues (excluding amortization of acquired intangible assets)		—			238		3,645		—			3,883
Direct expenses		3,496			353		4,187		8,529			16,565
Segment contribution	$	(3,496	)	$	701	$	172	$	(8,529	)	$	(11,152	)
Indirect expenses									375	(a)		375
Loss from operations												(11,527	)
(a) Components of other
Amortization									375
Total other								$	375

Financial information by segment for the nine months ended September 30, 2025 and 2024 is as follows:

	Nine Months Ended September 30, 2025
	Cell Therapy			BioBanking		Degenerative Disease			Other			Total
Net revenues	$	2,615			4,131		15,700			—			22,446
Cost of revenues (excluding amortization of acquired intangible assets)		—			649		12,051			—			12,700
Direct expenses		10,263			1,121		7,959			28,537			47,880
Segment contribution	$	(7,648	)	$	2,361	$	(4,310	)	$	(28,537	)	$	(38,134	)
Indirect expenses										1,116	(a)		1,116
Loss from operations													(39,250	)
(a) Components of other
Amortization										1,116
Total other									$	1,116

	Nine Months Ended September 30, 2024
	Cell Therapy			BioBanking		Degenerative Disease		Other			Total
Net revenues	$	—			3,857		32,231		—			36,088
Cost of revenues (excluding amortization of acquired intangible assets)		—			952		6,694		—			7,646
Direct expenses		12,383			1,216		14,385		28,159			56,143
Segment contribution	$	(12,383	)	$	1,689	$	11,152	$	(28,159	)	$	(27,701	)
Indirect expenses									1,377	(a)		1,377
Loss from operations												(29,078	)
(a) Components of other
Amortization									1,377
Total other								$	1,377